A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom

Advances in Therapy

Volumn 34, Issue 3, 2017, Pages 703-712

  Johnston, Robert L ^a,b   Carius, Hans Joachim ^c   Skelly, Adrian ^d   Ferreira, Alberto ^d   Milnes, Fran ^d   Mitchell, Paul ^e  

^a ROYAL COLLEGE OF OPHTHALMOLOGISTS   (United Kingdom)

^b GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c IQVIA   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Anti vascular endothelial growth factor; Neovascular age related macular degeneration; Pro re nata regimen; Ranibizumab; Real world data; Treat and extend regimen; Visual acuity

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; AUSTRALIA; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; TREND STUDY; UNITED KINGDOM; VISION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; ELECTRONIC HEALTH RECORD; FACTUAL DATABASE; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; AUSTRALIA; CHOROIDAL NEOVASCULARIZATION; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; RANIBIZUMAB; TREATMENT OUTCOME; UNITED KINGDOM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 85011265875     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-017-0483-1     Document Type: Article

References (22)

1. Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol (Chicago, Ill.: 1960) 2004;122:564–572.
2. Mario SP. Global data on visual impairments 2010. http://www.who.int/blindness/GLOBALDATAFINALforweb.pdf. Accessed May 9, 2016.
3. Wong TY, Wong T, Chakravarthy U, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115:116–26.
4. Mitchell P, Bressler N, Doan QV, et al. Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in australia by ranibizumab treatment. PLoS One. 2014;9:e101072.
5. Johnston RL, Lee AY, Buckle M, et al. UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group. Report IV: incidence of blindness and sight impairment in ranibizumab-treated patients. Ophthalmology. 2016;123:2386–92.
6. European Medicines Agency. Lucentis ranibizumab. EPAR summary for the public. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000715/WC500043548.pdf. Updated October 30, 2014. Accessed May 9, 2016.
7. Therapeutic Goods Administration. Australian Public Assessment Report for Ranibizumab. https://www.tga.gov.au/sites/default/files/auspar-lucentis.pdf. Accessed May 9, 2016.
8. NICE technology appraisal guidance [TA155]. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. https://www.nice.org.uk/guidance/ta155/resources/ranibizumab-and-pegaptanib-for-the-treatment-of-agerelated-macular-degeneration-82598316423109. Updated May 2012. Accessed May 9, 2016.
9. European Medicines Agency. Lucentis: EPAR-Product Information. Annex I—summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf. Updated May 11, 2016. Accessed Sept 27, 2016.
10. Novartis Pharmaceuticals Australia Pty Limited. LUCENTIS ranibizumab (rbe). Product information for inclusion in the Australian Register of therapeutic goods (The ARTG). https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2009-PI-00271-3&d=2016050916114622483. Updated March 24, 2016. Accessed May 9, 2016.
11. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679–80.
12. Tufail A, Xing W, Johnston R, Akerele T, McKibbin M, Downey L, Natha S, Chakravarthy U, Bailey C, Khan R, Antcliff R, Armstrong S, Varma A, Kumar V, Tsaloumas M, Mandal K, Bunce C. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. Report 1: visual acuity. The neovascular age-related macular degeneration database: multicenter study of 92,976 ranibizumab injections. Ophthalmology. 2014;121:1092–101.
13. Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol. 2016;100:914–917.
14. Hatz K, Prünte C. Treat and extend versus pro re nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 month study. Acta Ophthalmologica. 2017;95(1):e67–e72.
15. Novartis. Novartis announce licence change for leading sight loss treatment Lucentis (ranibizumab). http://newsroom.novartis.co.uk/UK/novartis-announce-licence-change-for-leading-sight-loss-treatment-lucentis-ranibizumab/s/b60c8753-51a4-4d9d-8aed-7c0c5bbfd972. Accessed May 9, 2016.
16. Gillies MC, Walton RJ, Arnold JJ, et al. Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. Ophthalmology. 2014;121:676–81.
17. International Society for Pharmacoepidemiology (ISPE). Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17:200–8.
18. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg (London, England). 2014;12:1500–1524.
19. Freund KB, Korobelnik J, Devenyi R, et al. treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina (Philadelphia, Pa.). 2015;35:1489–1506.
20. Hatz K, Prünte C. Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol. 2016;100:1341–5.
21. Boulanger-Scemama E, Querques G, About F, et al. Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol. 2015;38:620–7.
22. Liew G, Lee AY, Zarranz-Ventura J, et al. The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care. Eye (London, England). 2016;30:1462–1468.